Kinfo
Enovis Corporation logo

Enovis Corporation

CFXNYSEHealthcare·US · USD
$24.24
-2.37 (-8.91%)
Prices as of August 10, 2026 · live

Price

Key statistics

Valuation
Market cap1.30B USD
Enterprise value2.86B USD
Trailing P/E28.55
Forward P/E14.52
PEG ratio-0.86
Price / sales0.34
Price / book-13.06
Profitability
Gross margin42.04%
Operating margin0.00%
Profit margin41.87%
Return on assets2.32%
Return on equity97.94%
Income (TTM)
Revenue3.85B USD
Gross profit1.61B USD
EBITDA557.14M USD
Net income71.66M USD
Diluted EPS$0.00
Rev. growth (YoY)0.01%
Balance sheet
Total cash0.00 USD
Total debt2.25B USD
Debt / equity50.39
Current ratio2.19
Book value / share$0.83
Cash flow (TTM)
Operating cash flow340.01M USD
Levered free cash flow2.50B USD
Shares & price
Shares outstanding53.78M
Float0.00
Held by institutions0.00%
Beta0.00
50-day MA$0.00
200-day MA$0.00
52-week high$34.28
52-week low$19.14
Earnings (EPS)
DateEst.ActualSurprise2022-02-221.721.77+2.91%2021-11-041.601.62+1.25%2021-07-281.591.68+5.66%2021-04-291.191.32+10.92%2021-02-181.491.53+2.68%
About Enovis Corporation

Enovis Corporation is a medical technology company focused on developing and manufacturing innovative orthopedic care and rehabilitation solutions. The company operates primarily through two business segments: Prevention & Recovery, which encompasses bracing, supports, and other therapies designed to prevent injury and enhance patient recovery, and Reconstructive, which provides products for joint replacement and surgical interventions aimed at restoring patient mobility. Enovis has evolved from its origins as Colfax Corporation, previously a diversified industrial manufacturing firm, to a dedicated medtech enterprise following significant acquisitions and strategic divestitures, most notably the purchase of DJO for orthopedic platforms and the spinoff of its fabrication technology segment as ESAB Corporation. Leveraging a heritage of operational excellence and continuous improvement—principles rooted in the company’s founding by the Rales brothers—Enovis is committed to driving better clinical outcomes and transforming workflows in healthcare settings. It serves hospitals, clinics, and healthcare providers worldwide, contributing to advancements in patient care through innovations that improve mobility and quality of life. Today, Enovis is recognized for its strong focus on growth, industry leadership in orthopedics, and its vital role in the broader health technology sector.

Sector
Healthcare
Industry
Medical Devices
CEO
Mr. Damien McDonald
Employees
7,367
Headquarters
Wilmington, DE, United States

Frequently asked questions about Enovis Corporation